TY - JOUR AU - Webster, D. P. AU - Klenerman, P. AU - Dusheiko, G. M. PY - 2015 DA - 2015// TI - Hepatitis C JO - Lancet VL - 385 UR - https://doi.org/10.1016/S0140-6736(14)62401-6 DO - 10.1016/S0140-6736(14)62401-6 ID - Webster2015 ER - TY - JOUR AU - Razavi, H. AU - Waked, I. AU - Sarrazin, C. AU - Myers, R. P. AU - Idilman, R. AU - Calinas, F. PY - 2014 DA - 2014// TI - The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm JO - J Viral Hepat VL - 21 UR - https://doi.org/10.1111/jvh.12248 DO - 10.1111/jvh.12248 ID - Razavi2014 ER - TY - JOUR AU - Razavi, H. AU - Elkhoury, A. C. AU - Elbasha, E. AU - Estes, C. AU - Pasini, K. AU - Poynard, T. PY - 2013 DA - 2013// TI - Chronic hepatitis C virus (HCV) disease burden and cost in the United States JO - Hepatology VL - 57 UR - https://doi.org/10.1002/hep.26218 DO - 10.1002/hep.26218 ID - Razavi2013 ER - TY - JOUR PY - 2011 DA - 2011// TI - Clinical Practice Guidelines: management of hepatitis C virus infection JO - J Hepatol VL - 55 UR - https://doi.org/10.1016/j.jhep.2011.02.023 DO - 10.1016/j.jhep.2011.02.023 ID - ref4 ER - TY - JOUR AU - Antaki, N. AU - Craxi, A. AU - Kamal, S. AU - Moucari, R. AU - der, M. S. AU - Haffar, S. PY - 2010 DA - 2010// TI - The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report JO - Liver Int VL - 30 UR - https://doi.org/10.1111/j.1478-3231.2009.02188.x DO - 10.1111/j.1478-3231.2009.02188.x ID - Antaki2010 ER - TY - JOUR AU - Bunchorntavakul, C. AU - Reddy, K. R. PY - 2015 DA - 2015// TI - Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection JO - Aliment Pharmacol Ther VL - 42 UR - https://doi.org/10.1111/apt.13264 DO - 10.1111/apt.13264 ID - Bunchorntavakul2015 ER - TY - JOUR AU - McCormack, P. L. AU - Lyseng-Williamson, K. A. PY - 2016 DA - 2016// TI - Daclatasvir in hepatitic C virus infection: a guide to its use in the EU JO - Drugs Ther Perspect VL - 32 UR - https://doi.org/10.1007/s40267-015-0272-3 DO - 10.1007/s40267-015-0272-3 ID - McCormack2016 ER - TY - JOUR AU - Sulkowski, M. S. AU - Gardiner, D. F. AU - Rodriguez-Torres, M. AU - Reddy, K. R. AU - Hassanein, T. AU - Jacobson, I. PY - 2014 DA - 2014// TI - Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMoa1306218 DO - 10.1056/NEJMoa1306218 ID - Sulkowski2014 ER - TY - JOUR AU - Asselah, T. PY - 2014 DA - 2014// TI - Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy JO - J Hepatol VL - 61 UR - https://doi.org/10.1016/j.jhep.2014.04.042 DO - 10.1016/j.jhep.2014.04.042 ID - Asselah2014 ER - TY - JOUR AU - Hsu, C. S. AU - Kao, J. H. PY - 2016 DA - 2016// TI - Management of hepatitis C patients with decompensated liver disease JO - Expert Rev Gastroenterol Hepatol. VL - 10 UR - https://doi.org/10.1586/17474124.2016.1143775 DO - 10.1586/17474124.2016.1143775 ID - Hsu2016 ER - TY - STD TI - AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. 2016. http://www.hcvguidelines.org/full-report/unique-patient-populations-patients-decompensated-cirrhosis. Accessed 11 Nov 2016. UR - http://www.hcvguidelines.org/full-report/unique-patient-populations-patients-decompensated-cirrhosis ID - ref11 ER - TY - STD TI - EASL. Recommendations on treatment of hepatitis C 2016. 2016 http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/easl-recommendations-on-treatment-of-hepatitis-c-2016. Accessed 11 Nov 2016. UR - http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/easl-recommendations-on-treatment-of-hepatitis-c-2016 ID - ref12 ER - TY - STD TI - Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. third. Bayesian data analysis. Boca Raton: CRC Press; 2013. ID - ref13 ER - TY - JOUR AU - Greenland, S. PY - 2007 DA - 2007// TI - Prior data for non-normal priors JO - Stat Med VL - 26 UR - https://doi.org/10.1002/sim.2788 DO - 10.1002/sim.2788 ID - Greenland2007 ER - TY - JOUR AU - Greenland, S. PY - 2006 DA - 2006// TI - Bayesian perspectives for epidemiological research: I. Foundations and basic methods JO - Int J Epidemiol VL - 35 UR - https://doi.org/10.1093/ije/dyi312 DO - 10.1093/ije/dyi312 ID - Greenland2006 ER - TY - JOUR AU - Greenland, S. PY - 2007 DA - 2007// TI - Bayesian perspectives for epidemiological research. II. Regression analysis JO - Int J Epidemiol VL - 36 UR - https://doi.org/10.1093/ije/dyl289 DO - 10.1093/ije/dyl289 ID - Greenland2007 ER - TY - JOUR AU - Young, J. AU - Scherrer, A. U. AU - Gunthard, H. F. AU - Opravil, M. AU - Yerly, S. AU - Boni, J. PY - 2011 DA - 2011// TI - Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study JO - HIV Med VL - 12 UR - https://doi.org/10.1111/j.1468-1293.2010.00885.x DO - 10.1111/j.1468-1293.2010.00885.x ID - Young2011 ER - TY - JOUR AU - Wedemeyer, H. PY - 2015 DA - 2015// TI - Towards interferon-free treatment for all HCV genotypes JO - Lancet VL - 385 UR - https://doi.org/10.1016/S0140-6736(15)60605-5 DO - 10.1016/S0140-6736(15)60605-5 ID - Wedemeyer2015 ER - TY - JOUR AU - Hezode, C. AU - Bronowicki, J. P. PY - 2016 DA - 2016// TI - Ideal oral combinations to eradicate HCV: the role of ribavirin JO - J Hepatol VL - 64 UR - https://doi.org/10.1016/j.jhep.2015.09.009 DO - 10.1016/j.jhep.2015.09.009 ID - Hezode2016 ER - TY - JOUR AU - Foster, G. R. AU - Irving, W. L. AU - Cheung, M. C. AU - Walker, A. J. AU - Hudson, B. E. AU - Verma, S. PY - 2016 DA - 2016// TI - Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis JO - J Hepatol. VL - 64 UR - https://doi.org/10.1016/j.jhep.2016.01.029 DO - 10.1016/j.jhep.2016.01.029 ID - Foster2016 ER - TY - JOUR AU - Leroy, V. AU - Angus, P. AU - Bronowicki, J. P. AU - Dore, G. J. AU - Hezode, C. AU - Pianko, S. PY - 2016 DA - 2016// TI - Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized Phase III study (ALLY-3+) JO - Hepatology. VL - 63 UR - https://doi.org/10.1002/hep.28473 DO - 10.1002/hep.28473 ID - Leroy2016 ER - TY - JOUR AU - Wyles, D. L. AU - Ruane, P. J. AU - Sulkowski, M. S. AU - Dieterich, D. AU - Luetkemeyer, A. AU - Morgan, T. R. PY - 2015 DA - 2015// TI - Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1 JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1503153 DO - 10.1056/NEJMoa1503153 ID - Wyles2015 ER - TY - JOUR AU - Nelson, D. R. AU - Cooper, J. N. AU - Lalezari, J. P. AU - Lawitz, E. AU - Pockros, P. J. AU - Gitlin, N. PY - 2015 DA - 2015// TI - All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study JO - Hepatology VL - 61 UR - https://doi.org/10.1002/hep.27726 DO - 10.1002/hep.27726 ID - Nelson2015 ER - TY - JOUR AU - Poordad, F. AU - Schiff, E. R. AU - Vierling, J. M. AU - Landis, C. AU - Fontana, R. J. AU - Yang, R. PY - 2016 DA - 2016// TI - Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence JO - Hepatology VL - 63 UR - https://doi.org/10.1002/hep.28446 DO - 10.1002/hep.28446 ID - Poordad2016 ER - TY - JOUR AU - Coilly, A. AU - Fougerou-Leurent, C. AU - Ledinghen, V. AU - Houssel-Debry, P. AU - Duvoux, C. AU - Martino, V. PY - 2016 DA - 2016// TI - Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study JO - J Hepatol VL - 65 UR - https://doi.org/10.1016/j.jhep.2016.05.039 DO - 10.1016/j.jhep.2016.05.039 ID - Coilly2016 ER - TY - JOUR AU - Welzel, T. M. AU - Petersen, J. AU - Herzer, K. AU - Ferenci, P. AU - Gschwantler, M. AU - Wedemeyer, H. PY - 2016 DA - 2016// TI - Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort JO - Gut VL - 65 UR - https://doi.org/10.1136/gutjnl-2016-312444 DO - 10.1136/gutjnl-2016-312444 ID - Welzel2016 ER - TY - JOUR AU - Hezode, C. AU - Ledinghen, V. AU - Fontaine, H. AU - Zoulim, F. AU - Lebray, P. AU - Boyer, N. PY - 2015 DA - 2015// TI - Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use program (abstract LP05) JO - J Hepatol VL - 62 UR - https://doi.org/10.1016/S0168-8278(15)30159-8 DO - 10.1016/S0168-8278(15)30159-8 ID - Hezode2015 ER - TY - JOUR AU - Nakamoto, S. AU - Kanda, T. AU - Shirasawa, H. AU - Yokosuka, O. PY - 2015 DA - 2015// TI - Antiviral therapies for chronic hepatitis C virus infection with cirrhosis JO - World J Hepatol VL - 7 UR - https://doi.org/10.4254/wjh.v7.i8.1133 DO - 10.4254/wjh.v7.i8.1133 ID - Nakamoto2015 ER - TY - JOUR AU - Boccaccio, V. AU - Bruno, S. PY - 2014 DA - 2014// TI - Management of HCV patients with cirrhosis with direct acting antivirals JO - Liver Int VL - 34 UR - https://doi.org/10.1111/liv.12391 DO - 10.1111/liv.12391 ID - Boccaccio2014 ER - TY - JOUR AU - Gambato, M. AU - Lens, S. AU - Navasa, M. AU - Forns, X. PY - 2014 DA - 2014// TI - Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation JO - J Hepatol VL - 61 UR - https://doi.org/10.1016/j.jhep.2014.07.020 DO - 10.1016/j.jhep.2014.07.020 ID - Gambato2014 ER - TY - STD TI - CIOMS. International ethical guidelines for epidemiological studies. 2009. http://www.cioms.ch/index.php/publications/printablev3/541/showCategory/65/bioethics-and-health-policy-guidelines-and-other-normative-documents. Accessed 9 Dec 2016. UR - http://www.cioms.ch/index.php/publications/printablev3/541/showCategory/65/bioethics-and-health-policy-guidelines-and-other-normative-documents ID - ref31 ER -